← Enzyme Inhibition/Allosteric Regulation & Cooperativity

8. Allosteric Regulation & Cooperativity

Reading time: ~45 minutes | Key topics: Allosteric enzymes, Hill equation, MWC & KNF models, feedback inhibition, covalent modification, zymogens

Allosteric Enzymes

Allosteric enzymes do not follow classical Michaelis-Menten kinetics. Instead of hyperbolic curves, they display sigmoidal (S-shaped) saturation curves arising from cooperative interactions between multiple subunits.

Defining Features

  • Multiple subunits: Oligomeric enzymes, each subunit with its own active site.
  • Cooperative binding: Substrate binding to one subunit alters affinity of neighboring subunits (positive or negative cooperativity).
  • Regulatory sites: Distinct from the active site. Allosteric activators shift the curve left; inhibitors shift it right.

Their sigmoidal kinetics make allosteric enzymes exquisitely sensitive near $K_{0.5}$ (the half-maximal velocity concentration, analogous to $K_m$), making them ideal metabolic switches.

The Hill Equation

The Hill equation (1910) generalizes Michaelis-Menten kinetics to account for cooperativity:

$$v_0 = \frac{V_{\max}[S]^n}{K_{0.5}^n + [S]^n}$$

where $n$ is the Hill coefficient and $K_{0.5}$ is the substrate concentration at half-maximal velocity. The Hill coefficient reflects the degree of cooperativity:

Interpreting the Hill Coefficient

  • $n > 1$: Positive cooperativity — substrate binding to one subunit enhances binding at subsequent subunits. The curve is sigmoidal.
  • $n = 1$: No cooperativity — the Hill equation reduces to the standard Michaelis-Menten equation with a hyperbolic curve.
  • $n < 1$: Negative cooperativity — substrate binding to one subunit decreases affinity at remaining subunits. Rare but observed (e.g., some tyrosine kinases).

The Hill plot linearizes this equation by taking logarithms:

$$\log\frac{v_0}{V_{\max} - v_0} = n\log[S] - n\log K_{0.5}$$

The slope gives $n$ and the x-intercept gives $\log K_{0.5}$. Note that $n$ is always $\leq$ the actual number of binding sites. For hemoglobin (4 sites), $n \approx 2.8$, indicating strong but imperfect cooperativity.

Concerted Model (MWC)

The Monod-Wyman-Changeux (MWC) model (1965) assumes allosteric enzymes exist in two conformational states:

The Two-State Model

  • T state (Tense): Low-affinity, less active conformation. Predominates in the absence of substrate.
  • R state (Relaxed): High-affinity, more active conformation. Favored by substrate binding.
  • Key constraint: All subunits must be in the same state simultaneously — there are no hybrid T/R conformations. The entire oligomer switches as a unit (concerted transition).

The allosteric constant $L_0$ describes the equilibrium between the two states in the absence of ligand:

$$L_0 = \frac{[T_0]}{[R_0]}$$

For an enzyme with $n$ subunits, defining $\alpha = [S]/K_R$ (normalized substrate concentration relative to the R-state dissociation constant) and $c = K_R/K_T$ (ratio of dissociation constants), the fractional saturation is:

$$\bar{Y} = \frac{L_0 c\alpha(1+c\alpha)^{n-1} + \alpha(1+\alpha)^{n-1}}{L_0(1+c\alpha)^n + (1+\alpha)^n}$$

Allosteric activators stabilize R (decrease $L_0$); inhibitors stabilize T (increase $L_0$). The MWC model elegantly explains both homotropic (substrate cooperativity) and heterotropic effects (activators/inhibitors). Its limitation: it predicts only positive cooperativity.

Sequential Model (KNF)

The Koshland-Nemethy-Filmer (KNF) model (1966) allows individual subunits to change conformation independently upon ligand binding, unlike the all-or-none MWC model.

Core Principles

  • Induced fit: Each subunit undergoes a conformational change only when it binds ligand. Unliganded subunits remain in the T state.
  • Sequential transitions: Hybrid states are allowed — some subunits can be in the R state while others remain in the T state (e.g., TRRT in a tetramer).
  • Subunit interactions: The conformational change in one subunit alters the interaction energy with neighboring subunits, which can either favor or disfavor subsequent binding.

Interaction constants ($K_{AB}$) for each subunit interface determine whether conformational changes create favorable (positive cooperativity) or unfavorable (negative cooperativity) interactions.

MWC vs. KNF Comparison

MWC (Concerted)

  • All-or-none conformational switch
  • Only T and R states exist
  • Predicts only positive cooperativity
  • Fewer parameters, more elegant

KNF (Sequential)

  • Individual subunit transitions
  • Hybrid states are allowed
  • Predicts both positive and negative cooperativity
  • More parameters, more flexible

Feedback Inhibition

Feedback inhibition (end-product inhibition) is a fundamental regulatory strategy in metabolism. The final product of a biosynthetic pathway inhibits the enzyme that catalyzes the first committed step of that pathway. This prevents wasteful overproduction and conserves metabolic resources.

Classic Example: Aspartate Transcarbamoylase (ATCase)

ATCase catalyzes the first committed step of pyrimidine biosynthesis: the condensation of aspartate and carbamoyl phosphate to form N-carbamoylaspartate. It is the paradigm for allosteric regulation.

  • CTP (the end product of the pyrimidine pathway) acts as an allosteric inhibitor, shifting the T/R equilibrium toward the T state and shifting the sigmoidal curve to the right.
  • ATP acts as an allosteric activator, signaling that purine nucleotides are abundant and pyrimidine synthesis should proceed. ATP stabilizes the R state.
  • ATCase has a quaternary structure of $c_6r_6$: six catalytic subunits (organized as two trimers) and six regulatory subunits (organized as three dimers). CTP and ATP bind to the regulatory subunits.

Isoleucine Biosynthesis

In bacteria, isoleucine inhibits threonine deaminase, the first enzyme committed to isoleucine synthesis from threonine. This is an example of simple linear feedback inhibition. When branched pathways share a common first step, more sophisticated regulatory strategies are used, including cumulative inhibition, sequential inhibition, and isozyme-specific inhibition.

Covalent Modification

Many enzymes are regulated by reversible covalent modification. The most common is phosphorylation by protein kinases (using ATP), reversed by protein phosphatases:

$$E_{\text{inactive}} \xrightleftharpoons[\text{phosphatase}]{\text{kinase} + \text{ATP}} E\text{-P}_{\text{active}}$$

Phosphorylation activates some enzymes (glycogen phosphorylase) and inactivates others (glycogen synthase).

Signal Amplification Through Cascades

A major advantage of covalent modification is cascading amplification. A single hormone molecule activating a single kinase can lead to the phosphorylation of many target enzymes. If those targets are themselves kinases, the amplification is multiplicative:

$$\text{1 hormone} \to n_1 \text{ kinase}_1 \to n_1 n_2 \text{ kinase}_2 \to n_1 n_2 n_3 \text{ target enzymes}$$

In the glycogenolysis cascade, a single epinephrine molecule can lead to the release of approximately 10$^8$ glucose molecules — a 100-million-fold amplification.

Other Covalent Modifications

  • Adenylylation: Addition of an AMP group. Regulates glutamine synthetase in E. coli via a bicyclic cascade involving adenylyltransferase.
  • ADP-ribosylation: Transfer of ADP-ribose from NAD$^+$ to target proteins. Exploited by cholera toxin (ADP-ribosylates G$_s\alpha$) and pertussis toxin (ADP-ribosylates G$_i\alpha$).
  • Ubiquitination: Attachment of ubiquitin chains, targeting proteins for proteasomal degradation. Critical for cell cycle regulation and protein quality control.
  • Acetylation/methylation: Modulation of histones and metabolic enzymes. Central to epigenetic regulation and metabolic adaptation.

Zymogen Activation

Zymogens (proenzymes) are inactive precursors activated by irreversible proteolytic cleavage. This one-way switch allows safe storage and rapid, localized activation of potentially destructive enzymes.

Digestive Enzyme Zymogens

  • Pepsinogen → Pepsin: Secreted by gastric chief cells. Autocatalytic activation at pH < 5 in the stomach; the pro-peptide is cleaved away by the acidic environment and by active pepsin itself.
  • Trypsinogen → Trypsin: Secreted by the pancreas. Activated by enterokinase (enteropeptidase) in the duodenum, which cleaves a specific Lys-Ile bond. Trypsin then activates additional trypsinogen molecules (autocatalysis) and other pancreatic zymogens.
  • Chymotrypsinogen → Chymotrypsin: Activated by trypsin cleavage, followed by autolytic processing to form the mature, fully active enzyme with two polypeptide chains linked by disulfide bonds.

The Blood Clotting Cascade

The coagulation cascade is the most elaborate example of zymogen activation, involving a sequential series of protease activations that converge to form a fibrin clot. Two pathways feed into a common pathway:

  • Intrinsic pathway: Initiated by contact activation (Factor XII → XIIa) when blood contacts exposed collagen at the site of vascular injury. Proceeds through Factors XI, IX, and VIII.
  • Extrinsic pathway: Triggered by tissue factor (TF) released from damaged cells, which binds Factor VII/VIIa. This is the faster pathway and the primary initiator of coagulation in vivo.
  • Common pathway: Both pathways converge at Factor X activation. Factor Xa, together with Factor Va on a phospholipid surface (prothrombinase complex), converts prothrombin → thrombin. Thrombin then cleaves fibrinogen → fibrin, forming the insoluble clot.

Each step amplifies the signal enormously. The cascade design provides both amplification and multiple points for regulatory control (e.g., antithrombin III, protein C, tissue factor pathway inhibitor).

Key Concepts

1. Allosteric enzymes display sigmoidal kinetics due to cooperative interactions between subunits. They are described by the Hill equation with $K_{0.5}$ replacing $K_m$.

2. The Hill coefficient $n$ quantifies cooperativity:$n > 1$ (positive), $n = 1$ (none), $n < 1$ (negative). It is determined from the slope of the Hill plot.

3. The MWC (concerted) model assumes all subunits switch between T and R states simultaneously. The allosteric constant $L_0 = [T_0]/[R_0]$ governs the equilibrium.

4. The KNF (sequential) model allows individual subunit conformational changes upon ligand binding, accommodating both positive and negative cooperativity through subunit interaction energies.

5. Feedback inhibition regulates metabolic flux by having the end product of a pathway inhibit the first committed enzyme (e.g., CTP inhibits ATCase in pyrimidine biosynthesis).

6. Reversible covalent modification (especially phosphorylation by kinases/phosphatases) provides rapid, amplifiable on/off switching with cascading signal amplification.

7. Zymogen activation through irreversible proteolytic cleavage provides a unidirectional control mechanism, exemplified by digestive enzymes and the blood clotting cascade.

← Enzyme InhibitionDNA & RNA Structure →